UNSPSC 51161714: Bemegride

This classification denotes a cns stimulant with the molecular formula C8H13NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 57DQA39DO2, chemically known as 3,3-methylethylilotarimide but generally known as bemegride, which bears US NIH Compound Identifier 2310. Bemegride most often comes in base or methyl forms. European Medicines Agency schedules Bemegride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05691MIG.

UNSPSC 51161714 Bemegride, a Commodity code, represents pharmaceutical products and related pharmacy services that state and local governments procure to support community health, employee benefits, and public health initiatives. Recent state and local solicitations under this code show procurement spanning naloxone and drug deactivation systems for public health response, on-site pharmacy services for government employee health plans, direct-to-manufacturer prescription programs, and bulk generic pharmaceuticals and over-the-counter products through cooperative purchasing. The issuing bodies include county health departments, county government human resources offices managing employee benefits, state health and human services commissions, and state-administered cooperative purchasing alliances serving multiple jurisdictions. Work ranges from emergency-response pharmaceutical procurement to ongoing pharmacy benefit administration and wholesale pharmaceutical supply contracts.

Solicitations cluster in Florida, Georgia, Texas, and Minnesota. Representative recent opportunities include Seminole County, Florida's IFB (due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding; Hall County, Georgia's RFQ/P #47-010 (due June 4, 2026) for on-site pharmacy services at a government clinic serving approximately 3,005 enrolled individuals with technical qualifications weighted at 80 percent and cost at 20 percent; Texas Health and Human Services Commission's RFI No. HHS0017013 (posted April 3, 2026) gathering market intelligence on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP (due March 26, 2026) to establish multiple contracts for generic pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon, with price competitiveness weighted at 75 percent and contract term of two years for new responders.